MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis

Ítems similars

• A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
  per: Hellings, Peter, et al.
  Publicat: (2015)
• A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
  per: Price, David, et al.
  Publicat: (2013)
• A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
  per: Scadding, Glenis, et al.
  Publicat: (2013)
• Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
  per: Price, David, et al.
  Publicat: (2013)
• A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
  per: Hellings, Peter, et al.
  Publicat: (2013)